Drug Repurposing: Far Beyond New Targets for Old Drugs

Oprea TI. Sense and nonsense in drug discovery: a chemical perspective. In: Kruse CG, Timmerman H, editors. Towards drugs of the future. Amsterdam: IOS Press; 2008. p. 29–36.

Schuster D, Laggner C, Langer T. Why drugs fail—a study on side effects in new chemical entities. Curr Pharmaceut Design. 2005;11:3545–59.

Lindsay MA. Target discovery. Nat Rev Drug Discov. 2003;2:831–8.

Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673–83.

Zhao S, Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PLoS ONE. 2010;5:e11764.

Service RF. Surviving the blockbuster syndrome. Science. 2004;303:1796–9.

Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006;116:2837–42.

Munos B. Lessons from 60 years of pharmaceutical innovation. Nature Rev Drug Discov. 2009;8:959–68.

Chong CR, Sullivan DJ. New uses for old drugs. Nature. 2006;448:645–6.

Oprea TI, Nielsen SK, Ursu O, Yang JJ, Taboureau O, Mathias SL, et al. Associating drugs, targets, clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol Inf. 2011;30:100–11.

Oprea TI. Virtual screening in lead discovery: a viewpoint. Molecules. 2002;7:51–62.

Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994;91:12013–7.

Kurumbail RG, Stevens AM, Gierse JK, Mcdonald JJ, Stegeman RA, Pak JA, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384:644–8.

Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563–8.

Celebrex® (celecoxib) capsules package information, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226

Merck & Co., Inc. Merck announces voluntary worldwide withdrawal of Vioxx® (press release) Whitehouse Station, NJ; 2004 Sep 30.

Da Silva GMS, Lima LM, Fraga CAM, Sant’Anna CMR, Barreiro EJ. The molecular basis for coxib inhibition of p38α MAP kinase. Bioorg Med Chem Lett. 2005;15:3506–9.

PDSP (Psychoactive Drugs Screening Program) certified data, http://pdsp.med.unc.edu/pdsp.php?knowID=&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=celecoxib&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query

Weber W, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004;47:550–7.

Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. Data completeness—the Achilles heel of drug-target networks. Nat Biotechnol. 2008;26:983–4.

Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008;321:263–6.

Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462:175–81.

Mestres J, Seifert SA, Oprea TI. Linking pharmacology to clinical records: cyclobenzaprine and its possible association with serotonin syndrome. Clin Pharmacol Ther. 2011;90:662–5.

Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, et al. Drug repurposing from an academic perspective. Drug Discov Today: Therap Strategies. 2011;8:61–9.

Lin BK, Clyne M, Walsh M, Gomez O, Yu W, Gwinn M, et al. Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. Am J Epidemiol. 2006;164:1–4.

Yang JO, Hwang S, Oh J, Bhak J, Sohn T-K. An integrated database-pipeline system for studying single nucleotide polymorphisms and diseases. BMC Bioinformatics. 2008;9:S19.

Strachan RT, Ferrara G, Roth BL. Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discov Today. 2006;11:708–16.

Cases M, Mestres J. A chemogenomic approach to drug discovery: focus on cardiovascular diseases. Drug Discov Today. 2009;14:479–85.

Flachner B, Lörincz Z, Carotti A, Nicolotti O, Kuchipudi P, Remez N, et al. A chemocentric approach to the identification of cancer targets. PLoS ONE. 2012;7:e0035582.

Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–52.

Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58:409–12.

Wermuth CG. The ‘SOSA’ approach: an alternative to high-throughput screening. Med Chem Res. 2001;10:431–9.

Curley D, Easey A. Drug repurposing and repatenting. Bio-Science Law Review. 2009;10:131–4.

Sanderson K. Big interest in heavy drugs. Nature. 2009;458:269.

Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol BioSyst. 2009;5:1051–7.

Briansó F, Carrascosa MC, Oprea TI, Mestres J. Cross-pharmacology analysis of G protein-coupled receptors. Curr Top Med Chem. 2011;11:1956–63.

Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm Med. 2010;24:151–9.

Collins FS. Mining for therapeutic gold. Nature Rev Drug Discov. 2011;10:397.

Lipworth WL, Kerridge IH, Day RO. Wrong questions, wrong answers? Are we getting the drugs we need? Clin Pharmacol Ther. 2012;91:367–9.

Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10:712–3.

Kinnings SL, Xie L, Fung KH, Jackson RM, Xie L, Bourne PE. The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol. 2010;6:e1000976.

Shigemizu D, Hu Z, Hung JH, Huang CL, Wang Y, Delisi C. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol. 2012;8:e1002347.